# Business Model & Commercialization Strategy

## Problem
Clinicians in outpatient and small-hospital settings triage patients using
fragmented tools: PACS viewers for imaging, EHR tables for labs/vitals, and
free-text notes read manually. Nothing fuses these into one risk view, and
AI-assisted triage tools that exist are often black-box, which clinicians
distrust and regulators scrutinize.

## Solution
The AI Healthcare Co-Pilot fuses imaging, tabular vitals/labs, and free-text
notes into a single triage view with transparent, explainable predictions
(Grad-CAM, SHAP) and a mandatory human sign-off step — designed to be trusted
by clinicians and defensible to regulators (explainability + audit trail).

## Target customers
- **Primary**: small-to-mid-size clinics and diagnostic centers without in-house
  radiology/cardiology specialists on every shift.
- **Secondary**: telehealth platforms needing a fast first-pass triage layer.
- **Tertiary**: hospital systems for a second-opinion / QA layer on high-volume
  reads (e.g., ER chest X-rays).

## Revenue model
- **SaaS subscription** per clinic, tiered by monthly case volume (e.g., $299–$1,999/mo).
- **Per-report usage fee** for high-volume or seasonal customers ($0.50–$2 per case).
- **Enterprise/API licensing** for EHR vendors and telehealth platforms to embed the co-pilot.
- **Premium add-ons**: custom model fine-tuning on a hospital's own historical data; compliance/audit reporting packages.

## Go-to-market
1. Pilot with 2-3 clinics for free in exchange for case studies and validation data.
2. Publish accuracy/explainability benchmarks against public datasets (X-ray, UCI heart) for credibility.
3. Partner with EHR/telehealth vendors for distribution instead of competing with them directly.
4. Target regulatory-light markets first (decision support, not autonomous diagnosis) to accelerate time-to-revenue while pursuing FDA/CE clearance for higher-risk features.

## Competitive edge
- **Explainability-first**: Grad-CAM + SHAP baked in from day one, not bolted on.
- **HITL by design**: positions the product as *augmenting* clinicians, easing adoption and regulatory risk versus autonomous-diagnosis competitors.
- **Multimodal fusion**: most competitors are single-modality point solutions (imaging-only or labs-only); fusing image + tabular + text gives a fuller risk picture.

## Cost structure
- Cloud inference/hosting, model retraining pipelines, clinical validation studies, compliance/regulatory costs, sales & clinical support staff.

## Key risks
- Regulatory classification (SaMD) risk depending on autonomy level offered.
- Liability and malpractice exposure — mitigated by mandatory HITL sign-off and audit logging.
- Data privacy/HIPAA compliance requirements for handling PHI.

## Milestones (12 months)
- Months 1-3: Validate on public datasets, harden explainability outputs, publish benchmark report.
- Months 4-6: Pilot with 2-3 clinics, collect real-world feedback, iterate on HITL UX.
- Months 7-9: Begin regulatory pathway consultation, add fine-tuning per-customer.
- Months 10-12: First paid contracts, EHR partnership discussions.
